menu
    • menu
    [{"orgOrder":0,"company":"AOP Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"AOP Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Undisclosed"},{"orgOrder":0,"company":"AOP Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"AOP Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Undisclosed"},{"orgOrder":0,"company":"AOP Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AOP Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Undisclosed"},{"orgOrder":0,"company":"AOP Health","sponsor":"RHEACELL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"allo-APZ2-CVU","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AOP Health \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"AOP Health \/ AOP Health"},{"orgOrder":0,"company":"AOP Health","sponsor":"RHEACELL","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"allo-APZ2-OTS","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AOP Health \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"AOP Health \/ AOP Health"}]

    Find Clinical Drug Pipeline Developments & Deals by AOP Health

    Menu

    AOP Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2-CVU

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : RHEACELL

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rheacell and AOP Health Unite for Butterfly Disease and Venous Wound Therapy

                            Details : The partnership aims to develop and deliver innovative cell therapies, Ebesanar and Amesanar for patients suffering from Butterfly Children’s Disease and Chronic Venous Wounds.

                            Product Name : Amesanar

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : allo-APZ2-CVU

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : RHEACELL

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2-OTS

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : RHEACELL

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rheacell and AOP Health Partner to Commercialize Cell Therapies in Europe

                            Details : Under the agreement, AOP will commercialize Rheacell’s two stem cell products, Ebesanar and Amesanar, in Europe, Turkey, Israel and the MENA region.

                            Product Name : Ebesanar

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : allo-APZ2-OTS

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : RHEACELL

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Landiolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves AOP Health’s Rapiblyk™ for Atrial Fibrillation and Flutter

                            Details : Rapiblyk (landiolol) is a β1-adrenergic receptor antagonist, small molecule drug candidate which is indicated for the treatment of supraventricular tachycardia.

                            Product Name : Rapiblyk

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Landiolol Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AOP Health Presents Latest Updates On BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the America...

                            Details : BESREMi (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon. It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi is designed to be self-administered subcutaneously...

                            Product Name : Besremi

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 13, 2022

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed

                            AOP Health

                            Austria arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (R...

                            Details : BESREMi (Ropeginterferon alfa-2b) is long-acting, mono-pegylated proline interferon, unique pharmacokinetic properties new level of tolerability, designed to be conveniently self-administered subcutaneously with pen once every two weeks, or up to monthly...

                            Product Name : Besremi

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 13, 2022

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth